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Despite the large number of potentially cytotoxic tumor-infiltrating (TIL)
and tumor-associated (TAL) lymphocytes accumulated in the peritoneal
cavity ascitic fluid and tumor tissue, advanced ovarian cancer is a progres-
sive disease, suggesting that TIL and TAL populations eventually become
functionally suppressed in vivo. Dendritic cells (DC) are the most powerful
professional antigen presenting cells known in humans and recently, ovar-
ian tumor antigen pulsed DC have been shown to elicit tumor specific
human leukocyte antigens (HLA)-class I-restricted cytotoxicity from the
peripheral blood of advanced ovarian cancer patients. In this study, we
have evaluated the potential of tumor antigen-pulsed fully mature DC
stimulation in restoring tumor-specific cytotoxicity in anergic TIL popula-
tions from advanced ovarian cancer patients. In addition, we have com-
pared tumor-specific T-cell responses induced by tumor antigen-loaded DC
in TIL to those induced in TAL and peripheral blood lymphocytes (PBL).
DC stimulation induced powerful cytotoxicity against autologous tumor
target cells in TIL-derived CD8+ T-cells from all patients tested, while
autologous Epstein—Barr virus (EBV)-transformed lymphoblastoid cell
lines (LCL) were not lysed. Killing of autologous tumor cells was higher
by CD8+ T-cells from TIL compared to PBL and TAL (P < 0.01) and was
more strongly inhibited by anti-HLA class I MAb (P < 0.05 compared to PBL
and TAL). Phenotypically, all cytotoxic T lymphocyte (CTL) populations
were CD3+/CD8+, with variable levels of CD56 expression. Finally,
although a marked Type 1 cytokine bias [ie, interferon-gamma/interleu-
kin-4 (IFN-ghigh/IL-4low)] was observable in all DC-stimulated CD8+ T-cell
populations, TIL derived CD8+ T-cells showed a higher percentage of IFN-g
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positive cells compared to TAL and PBL. Taken together, these data show
that tumor lysate-pulsed DC can consistently restore strong CD8+ CTL
responses from TIL against autologous ovarian cancer cells. DC-stimulated
TIL may represent a superior source of tumor-specific CTL for adoptive
T-cell immunotherapy for advanced ovarian cancer.
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Because ovarian cancer remains localized in the abdom-
inal cavity even in the advanced stages of the disease, it
has been suggested that the growth of this malignancy
could be related to a local phenomenon of immunosup-
pression(1,2). Supporting this hypothesis, local deficiency
of several antitumor immune effector mechanisms have
been previously reported in the peritoneal cavity of
patients with advanced stages of ovarian cancer(1—7).
Although the causes responsible for these impaired
immune responses are not yet completely understood,
several mechanisms have been suggested to account for
tumor-induced subversion of the immune system,
including soluble tumor-derived inhibitory factors(8—11),
tolerogenic or T-cell-deleting presentation of antigens by
ovarian tumor cells(12,13), or activation of inhibitory regu-
latory elements of the immune system(14).
Dendritic cells (DC) are highly potent antigen present-
ing cells of bone marrow origin that can stimulate both
primary and secondary T- and B-cell responses(15,16).
Recently, the combination of GM-CSF and interleukin-4
(IL-4) has been shown to generate large numbers of mye-
loid monocyte-derived DC(17—19). However, these DC are
still immature. Although they may effectively capture
antigens, immature DC lack full T-cell-stimulatory activ-
ity and are sensitive to the immunosuppressive effects of
several immunoregulatory cytokines that can be pro-
duced by tumors(16,20). In contrast, when full maturation
is induced by appropriate stimuli, such as monocyte-
conditioned medium, LPS, or a cocktail of inflammatory
cytokines(16,20,21) DC demonstrate a reduced ability to
phagocytose antigens, but show a significantly higher
production of key cytokines (eg, IL-12), increased
resistance to the immunosuppressive effects of IL-10,
increased expression of T-cell adhesion and costimulatory
molecules, and increased expression of chemokine recep-
tors that guide DC migration into lymphoid organs for
priming of antigen-specific T-cells(16,20). It is thus apparent
that the maturation stage of DC is critical for their optimal
use in immunization strategies(22—24).
One of the most important components for a success-
ful tumor specific adoptive immunotherapy is the acti-
vation and expansion of large amount of tumor specific
lymphocytes. In earlier studies, lymphocytes derived
from ascitic fluid and infiltrating tumor tissues of ovar-
ian cancer patients have been shown to contain tumor
specific cytotoxic T lymphocyte (CTL) precursors that
can be stimulated to specifically kill autologous ovarian
cancer cells(25—27). However, in several of these reports,
T-cells derived from ascitic fluid tumor-associated lym-
phocytes (TAL) and tumor tissue (tumor-infiltrating
lymphocytes; TIL) have been shown to be defective in
several immunologic functions when compared to per-
ipheral blood lymphocytes (PBL) including (a) poor abil-
ity to proliferate in presence of mitogens, phorbol esters,
or low doses of IL-2, (b) cytotoxic activity against auto-
logous or allogenic tumor cells, (c) effector activity in
assays of natural killing, and (d) expression of cytoplas-
mic CD3-z chain, which is essential for T-cell receptor
(TcR) signaling(27). Importantly, however, in some cases,
poor immune responses by explanted T lymphocytes
could be normalized upon in vitro culture with high
doses of recombinant IL-2(28), or by T-cell stimulation
with anti-CD3 and anti-CD28(29). It is therefore possible
that when properly stimulated by tumor-antigen pulsed
mature DC, which are endowed with high expression of
human leukocyte antigens (HLA) class I and II antigens
and costimulatory molecules(19), TAL or TIL may reverse
their anergic state and become a superior source of
tumor specific cytotoxic lymphocytes for adoptive
T-cell immunotherapy for advanced ovarian cancer.
In this study, we have evaluated and compared the
phenotype and cytotoxic activity of tumor lysate-
pulsed autologous DC stimulated CD8þ T lympho-
cytes derived from PBL, TAL, and TIL from advanced
ovarian cancer patients. Here we show that tumor
antigen-pulsed fully mature DC have the potential to
reverse the anergic state of TIL and TAL and that TIL
constitute a superior source of tumor specific CD8þ
CTL compared to PBL and TAL for potential use in
adoptive immunotherapy for ovarian cancer.
Materials and methods
Patients
Three patients who had undergone total abdominal hys-
terectomy bilateral salpingo oophorectomy and omen-
tectomy for advanced ovarian cancer provided tumor
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tissue, ascitic fluid, and peripheral blood lymphocytes.
Specimens were obtained at the time of surgery through
the Division of Gynecologic Oncology and the Pathology
Department at the University of Arkansas for Medical
Sciences (UAMS), Little Rock, AR, under approval of the
Institutional Review Board. All patients had stage III
ovarian cancer with serous papillary histology. Patients
1 was of age 65, while Patients 2 and 3 were 80 and 72
years old, respectively.
Tumor cell lines
Fresh autologous tumor cells were obtained from
multiple ovarian tumor biopsies from all patients.
Fresh tumor cell lines were maintained in RPMI 1640
(Invitrogen, Grand Island, NY), supplemented with
15% autologous ascitic fluid at 37C, 5% CO2. Briefly,
single cell suspensions were obtained by processing solid
tumor samples under sterile conditions at room tem-
perature. Viable tumor tissue was mechanically minced
in RPMI 1640 to portions no larger than 1—3 mm3 and
washed twice with RPMI 1640. The portions of minced
tumor were then placed into 250 ml trypsinizing flasks
containing 30 ml of enzyme solution [0.14% Collage-
nase Type I (Sigma, St. Louis, MO) and 0.01% DNAse
(Sigma, 2000 KU/mg)] in RPMI 1640, and incubated
on a magnetic stirring apparatus overnight at 4 C.
Enzymatically dissociated tumor was then filtered
through 150 mm nylon mesh to generate a single cell
suspension. The resultant cell suspension was then
washed twice in RPMI 1640 plus 10% ascitic fluid.
All experiments were performed with fresh or cryo-
preserved tumor cultures which had at least 90%
viability and contained >99% tumor cells.
Collection and isolation of PBL from ovarian cancer
patients
Peripheral blood was collected in heparinized tubes at the
time of surgery and before any blood transfusion and
processed as previously described(30,31), to separate the
mononuclear leukocytes from red blood cells by Ficoll-
Hypaque density gradient centrifugation. The leukocytes
were subsequently harvested, washed twice in phosphate
buffered saline (PBS, pH 7.2), and resuspended in RPMI
1640 plus 5% human AB serum (Gemini BioProcust,
Calabasas, CA) before being stained with monoclonal
antibodies or used in DC-stimulation experiments.
Isolation of TAL
Ascitic fluid specimens (250—900 ml) were obtained at
the time of surgery. Thorough hemostasis was performed
at the time of abdominal incision to avoid contamination
of ascitic fluid lymphocytes with PBL. Briefly, centri-
fuged cell pellets from ascitic samples were washed
twice in RPMI 1640, placed on discontinuous Ficoll-
Hypaque (75/100%) density gradients, and centrifuged
again to harvest TAL and tumor cells as previously
described by Whiteside et al.(32). Enriched TAL prepara-
tions were then washed twice in RPMI 1640 plus 10%
autologous plasma and either immediately activated
with Phorbol 12-myristate 13-acetate (PMA) and
ionomycin for intracellular cytokine studies, or incu-
bated overnight at 37C in tissue culture flasks before
collecting the TAL from the non-adherent population.
Isolation of TIL
Single cell suspensions were obtained by processing
solid tumor samples as described above. The resultant
cell suspension containing tumor cells and TIL was
then washed twice in RPMI 1640 plus 10% auto-
logous plasma and placed on discontinuous Ficoll-
Hypaque (75/100%) density gradients, and centri-
fuged again to harvest TIL and tumor cells as
described above for TAL(32). Enriched TIL prepar-
ations were then washed twice in RPMI 1640 plus
10% autologous plasma and either immediately acti-
vated with PMA and ionomycin for intracellular cyto-
kine studies, or incubated overnight in tissue culture
flasks at 37C before collecting the TIL from the non-
adherent population.
DC cultures and generation of ovarian tumor-
specific T-cells
The derivation of DC from the patients’ peripheral
blood mononuclear cells (PBMC), and their subse-
quent use for generation of ovarian tumor-specific
T-cells, was carried out essentially as described(30,31).
Ovarian tumor-specific CD8þ T-cells were derived
from all three advanced ovarian cancer patients from
lymphocytes obtained from the different anatomical
sites. Briefly, DC were generated from plastic-adherent
PBMC by culture in AIM-V medium (Invitrogen)
plus 800 U/ml GM-CSF (Immunex, Seattle, WA) and
1000 U/ml IL-4 (R&D Systems, Minneapolis, MN).
Cultures were fed by half-changes of AIM-V plus
GM-CSF and IL-4 every 2 days. Final maturation of
monocyte-derived DC was induced by exposure dur-
ing the last 48 h of culture (ie, day 6—day 8) to TNF-a
(1000 U/ml), IL-1b (500 U/ml) (R&D Systems), and
PGE2a (0.5 mM/ml) (Sigma). The DC purity (ie, cells
strongly expressing HLA-DRþ, CD86þ, CD83þ,
CD80þ, CD40þ, and CD14—) ranged from 62 to 90%
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of the total cell population, as previously character-
ized by our laboratory(19). After final maturation, DC
were harvested for pulsing with ovarian tumor lysate
obtained from 5 to 10 106 autologous tumor cells
cultured in RPMI 1640 plus 15% autologous ascites
and lysed by 3—4 freeze cycles (in liquid nitrogen) and
thaw cycles (room temperature) as previously
described(31). The cationic lipid DOTAP (Boehringer
Mannheim, Indianapolis, IN) was used to deliver the
tumor lysate into cells as described(31). Ovarian
tumor-specific CTLs were generated by culturing
responder PBMC, TAL and TIL (10—20 106 cells/well
in 6-well culture plates) (Costar, Cambridge, MA)
in AIM-V with tumor lysate-pulsed autologous
DC (ratios from 20 : 1 to 30 : 1 responder PBMC : DC).
The cultures were supplemented with recombin-
ant human IL-2 (10 U/ml; Aldesleukin, Chiron Thera-
peutics, Emeryville, CA) and restimulated once with
tumor antigen-pulsed DC after 10—14 days. At day
21—28, CD8þ T-cells were separated from the bulk
cultures by positive selection with CD8-Dynabeads
(Dynal Inc., Lake Success, NY) and further expanded
in number for 10—14 days using autologous or allo-
geneic irradiated PBL (5000 cGy) (1106 cells/well)
and anti-CD3 monoclonal antibody (MAb) (0.2mg/ml)
in AIM-V plus 5% heat inactivated autologous plasma
in 24-well plates (Costar) before being assayed for
CTL activity. In some experiments, Dynabead-
separated CD8þ T-cells were restimulated once more
with autologous lethally irradiated (ie, 10,000 cGy) tumor
cells at a 20:1 lymphocyte/tumor ratio or tumor lysate
pulsed DC before being tested in cytotoxicity assays or
being further expanded with allogeneic irradiated PBL
(5000 cGy) (1106 cells/well) and anti-CD3 MAb.
Flow cytometric analysis of surface antigens,
intracellular CD3z chain, and cytokines by ovarian
tumor-specific CTL from PBL, TAL, and TIL
Flow cytometric analysis of superficial antigens and
intracellular cytokine expression was conducted
essentially as previously described(31,32). Briefly, flow
cytometry for superficial antigen expression was per-
formed using directly conjugated MAbs against the
following markers: CD3, pan T-cells; CD4, T helper/
inducer; CD8, T cytotoxic/suppressor; CD19, B cells;
CD56, NK/K cells; CD25, the IL-2 receptor; anti-HLA-
DR; and anti TcR-a/b (all from Becton Dickinson,
San Jose, CA). Control isotype-matched FITC- or PE-
conjugated MAb were also obtained from Becton
Dickinson. For evaluation of the level of CD3z chain
in CD8þ T-cells, PBL, TAL, and TIL before and after
in vitro stimulation with ovarian tumor lysate pulsed
DC were harvested, stained with anti-CD8-FITC (Bec-
ton Dickinson), washed, and fixed with 2% paraformal-
dehyde in PBS for 20 min at room temperature. Cells
were then washed and permeabilized by incubation
in PBS plus 1% BSA and 0.5% saponin (S-7900, Sigma)
for 10 min at room temperature. Experimental and
control cells were stained with anti TcRz-PE (2H2D9-
IgG1k), or isotype control (Immunotech, Marseille,
France). After staining, cells were washed twice with
PBS plus 1% BSA and 0.5% saponin, once with PBS
plus 0.5% BSA, and fixed a second time with 2%
paraformaldehyde in PBS. All analyses were con-
ducted with a FACScan, utilizing cell Quest software
(Becton Dickinson).
For intracellular cytokine staining for interferon-
gamma (IFN-g) and IL-4 expression, CD8þ T-cells
obtained from PBL, TAL, and TIL at the beginning
of culture were activated by 50 ng/ml PMA and
500 ng/ml ionomycin for 6 h. 10 mg/ml Brefeldin A
was added for the final 3 h of incubation. Controls
(non-activated cultures) were incubated in the pres-
ence of Brefeldin A only. Cells were superficially
stained with anti-CD8-FITC or anti-CD8-PE Mab and
then washed and permeabilized by incubation in PBS
plus 1% BSA and 0.5% saponin for 10 min at room
temperature. Activated and control cells were stained
with FITC-anti-IFN-g and/or PE-anti-IL-4 and isotype-
matched controls (FITC-anti-Igg2a and PE-anti-Igg1)
from Becton Dickinson. Purified DC-stimulated
CD8þ T-cell populations (ie, day 21—28 of culture)
were also analyzed by two color flow cytometry for
simultaneous expression of IFN-g and IL-4 at the sin-
gle cell level. After staining, cells were washed twice
with PBS plus 1% BSA and 0.5% saponin, once with
PBS plus 0.5% BSA, and fixed a second time with 2%
paraformaldehyde in PBS.
Cytotoxic activity
A 6-h chromium (51Cr) release assay was performed
as previously described(30,31) to measure the cytotoxic
reactivity of DC-ovarian tumor antigen-stimulated
T lymphocytes. The Epstein—Barr virus (EBV)-trans-
formed lymphoblastoid B-cell line (LCL) derived
from the same cancer patients that provided the pri-
mary tumor cell targets was established by coculture
of PBMC with EBV-containing supernatant from the
B95.8 cell line in the presence of 1 mg/ml cyclosporin
A (Sandoz, Camberley, UK) and was maintained in
RPMI 1640 supplemented with 10% human AB
serum. To determine the molecular basis of target cell
lysis, 51Cr-labeled tumor targets were preincubated
with MAbs specific for monomorphic HLA class
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I (W6/32, 50mg/ml) or isotype control Mab. The
effector cells and 51Cr-labeled targets were then
incubated in a final volume of 200ml/microwell at
37C with 6% CO2.
Statistical analysis
Data were analyzed using Student’s t-test. All data
were expressed as mean percentages of positive
cells standard deviation (SD). In all tests, the differ-
ence was considered significant when P-values were
<0.05.
Results
Phenotypic analysis of lymphocytes from peripheral
blood, ascitic fluids, and tumor tissue
Flow cytometric analysis was used to determine the
phenotype of the populations of lymphocytes
obtained from PBL, TAL, and TIL before and after
the in vitro stimulation with autologous ovarian
tumor antigen loaded DC. The proportions of CD3þ,
CD8þ, and CD4þ T-cells in PBL, TAL, and TIL from
the three ovarian cancer patients evaluated in this
study before DC activation are described in Table 1.
CD3þ T-cells were the major lymphocyte population
in each tissue, with the percentage of CD4þ T-cells
greater than the percentage of CD8þ T-cells in PBL
and TAL (P< 0.01) (Table 1). In contrast, in all three
patients CD8þ T-cells and CD4þ T-cells were present
in equal numbers in TIL (Table 1). The PBL had the
highest CD4þ to CD8þ ratio (mean¼ 3.1:1), with TAL
exhibiting a mean ratio of 2.2:1 and TIL a ratio of 1:1
(Table 1). Starting lymphocyte populations were also
different in the percentage of CD56 and CD19 positive
lymphocytes, with PBL containing more CD56þ and
CD19þ cells compared to TAL and TIL (P< 0.05 and
P< 0.05 for both CD56 and CD19). The expression of
CD56 on T lymphocytes was further analyzed by two
color immunofluorescence (Table 1). By this techni-
que, the CD8þ T-cells were compared for coexpres-
sion of CD56. PBL contained more CD8þ/CD56þ T-
cells compared to TAL and TIL (P< 0.05 and P< 0.05
for both TAL and TIL).
After 21—28 days’ culture of tumor lysate pulsed
DC-stimulated PBL, TAL, and TIL, the striking major-
ity of cells were found to be TcR-abþ/CD3þ T-cells
(90—98%). PBL and TAL contained more CD4þ over
CD8þ T-cells (range from 55—88% and 42—65%, for
PBL and TAL, respectively). In contrast, in the TIL
populations derived from all three patients the per-
centage of CD8þ T-cells was the predominant over
that of CD4þ T-cells (range from 55—78%). Enriched
populations of CD8þ T-cells were isolated at this
time, and analyzed for expression of CD56 after a
further two or more weeks of culture. A variable
proportion of CD8/CD56-antigen positive cells was
detected in all CD8þ T-cells derived from PBL, TAL,
and TIL. However, as representatively shown for
Patient 1 (Fig. 1), tumor lysate DC-stimulated TIL con-
sistently expressed a higher percentage of CD8þ/
CD56þ T-cells compared to PBL (P< 0.01) and TAL
(P< 0.05). Further analysis revealed the populations
of CD8þ T-cells to be CD25þ, HLA-DRþ, and CD16—
(data not shown).
Expression of intracellular TcRz chain in ovarian
tumor antigen-stimulated T-cells
To evaluate whether the expression levels of TcRz
chain vary significantly in PBL, TAL, and TIL col-
lected from ovarian tumor patients before and/or
after DC-stimulation, we again took advantage of
flow cytometry. As shown in Table 2, the mean fluor-
escence intensity of TcRz chain expression was signifi-
cantly higher in CD8þ T-cells derived from PBL
compared to those from TAL and TIL (P< 0.05) in
Table 1. Subpopulations of mononuclear cells in PBL, TAL, and TIL from advanced ovarian cancer patients
Specific MAb
Patient 1*
PBL TAL TIL
Patient 2*
PBL TAL TIL
Patient 3*
PBL TAL TIL
CD3 62 32 51 59 42 49 69 39 44
CD4 46 21 24 46 28 23 50 27 25
CD8 15 10 25 13 12 25 17 12 21
CD19 14 3 2 10 4 3 12 2 2
CD56 11 4 3 12 4 2 9 3 2
CD8/CD56 5 2 3 7 3 2 6 1 2
CD4/CD8 ratio 3.0 2.1 1.0 3.5 2.3 0.9 2.9 2.3 1.2
PBL, peripheral blood lymphocytes; TAL, tumor-associated lymphocytes; TIL, tumor-infiltrating lymphocytes.
Values are percentage of PBL, TAL and TIL positive for a specific marker used in the cell staining.
*Percentage of Phenotype.
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all three patients. However, after DC stimulation and
expansion, no significant differences were found in
TcRz chain expression among CD8þ T-cells derived
from PBL compared to TAL and TIL (data not shown).
Tumor-specific CD8þ cytotoxic responses in PBL,
TAL, and TIL-derived CD8þ T-cells
Cytotoxicity assays on tumor antigen-loaded DC-
stimulated CD8þ T-cells were conducted after a min-
imum of 2 weeks after in vitro separation of pure
populations of CD8þ T-cells derived from PBL, TAL,
and TIL. HLA class I-restricted lysis of autologous
tumor cells was detectable in all lymphocyte popula-
tions studied (Fig. 2). The results represent the mean
of not less than three assays for each patient. Cytoto-
toxic activity of DC-stimulated CD8þ T-cells at an
effector:target cell ratio of 20:1 ranged from 12 to
36%, mean 28% (PBL), from 18 to 42%, mean 32%
(TAL) and from 30 to 66%, mean 55% (TIL) for Patient
1; from 20 to 38%, mean 25% (PBL), from 18 to 39%,
mean 29% (TAL) and from 32 to 56%, mean 48% (TIL)
for Patient 2, and from 16 to 32%, mean 23% (PBL),
from 15 to 30%, mean 25% (TAL) and from 40 to 71%,
mean 60% (TIL) for Patient 3. In all cases low or
negligible cytotoxicity was observed against autolo-
gous EBV-transformed LCL and against natural
killer-sensitive K562 cells (Fig. 2). Blocking studies
indicated that in all cases tumor-specific lysis by
CD8þ T-cells was inhibited by MAb specific for
HLA class I, the range of inhibition being from 15 to
51% (PBL), from 25 to 61% (TAL), and from 35 to 95%
(TIL) for the three patients. In contrast with the tumor
specific cytotoxicity consistently observed with DC-
stimulated CD8þ T-cells from TIL, populations of
freshly isolated TIL (and TAL) showed no cytotoxicity
against autologous tumor targets.
Intracellular cytokine expression by ovarian tumor
antigen-specific T-cells
To determine the patterns of Type 1 and Type 2
cytokine expression in the populations of CD8þ T
10
4
10
3
10
2
10
1
10
0
10
4
10
3
10
2
10
1
10
0
10
4
10
3
10
2
10
1
10
0
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
TAL 22%
PBL 18%
TIL 40%
CD56-PE
CD
8-
FI
TC
Fig. 1. Two-color flow cytometric analysis of CD56 expression by
ovarian tumor-specific CD8þ T-cells in peripheral blood
lymphocytes, tumor-associated lymphocytes and tumor-
infiltrating lymphocytes from a representative patient after in vitro
stimulation with tumor antigen-loaded dendritic cells.
Table 2. Expression of TcRz chain in CD8þ T-cells derived
from PBL, TAL, and TIL from advanced ovarian cancer patients
Patient 1
%
MFI Patient 2
%
MFI Patient 3
%
MFI
PBL 100 30 100 49 100 38
TAL 95 18 99 22 96 26
TIL 97 11 97 12 94 14
MFI, mean fluorescence intensity; PBL, peripheral blood lym-
phocytes; TAL, tumor-associated lymphocytes; TIL, tumor-
infiltrating lymphocytes.
Lymphocyte population at the beginning of culture.
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lymphocytes collected from PBL, TAL, and TIL, two
color flow cytometric analysis of intracellular IFN-g
or IL-4 expression by CD8þ T-cells was performed
before and after in vitro culture with ovarian tumor
antigen-loaded autologous DC. As described in Table 3,
at the beginning of culture, significantly more CD8þ
T-cells from TIL expressed IFN-g after stimulation
with PMA and ionomycin compared to TAL and
PBL-derived CD8þ T-cells (P< 0.05). In contrast,
IL-4 expression was found at low, but significantly
higher levels in PBL (P< 0.05) when compared to
TAL and TIL (Table 3). When pure populations of
CD8þ T-cells were tested after separation and
further in vitro expansion, significantly higher
numbers of CD8þ T-cells from TIL were found
to contain intracellular IFN-g compared to CD8þ
T-cells derived from TAL and PBL (Fig. 3). IL-4
was again significantly higher in CD8þ T-cells
derived from PBL when compared to the expres-
sion of CD8þ T-cells obtained from TAL and TIL
(Fig. 3). Similar results were consistently obtained
in several repetitive analyses for all patients. Unacti-
vated (ie, resting) CD8þ T-cells failed to stain for IFN-g
or IL-4, and similarly, FITC-anti-IgG2a and PE-anti-IgG1
isotype controls did not stain either activated or unac-
tivated CD8þ T-cells (data not shown).
Discussion
DC are the most potent antigen-presenting cells
known in humans and play a crucial role during the
priming and reactivation of antigen specific immune
responses(16—23). This unique function as well as the
recent standardization of DC culture conditions in
vitro has provided the opportunity to evaluate their
potential for the immunological treatment of cancer
Table 3. Percentage of IFN-g and IL-4 positive CD8þ T-cells
from PBL, TAL, and TIL from advanced ovarian cancer patients
Patient 1
IFN-g
IL-4 Patient 2
IFN-g
IL-4 Patient 3
IFN-g
IL-4
PBL 12 5 20 4 14 4
TAL 22 2 32 1 25 2
TIL 43 1 49 1 46 1
IFN-IFN-g interferon-gamma; IL-4, interleukin-4; PBL, periph-
eral blood lymphocytes; TAL, tumor-associated lymphocytes;
TIL, tumor-infiltrating lymphocytes.
Lymphocyte population at the beginning of culture.
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Fig. 2. Tumor specific CD8þ cytotoxic T lymphocytes responses induced in peripheral blood lymphocytes, tumor-associated lymphocytes
and tumor-infiltrating lymphocytes by tumor lysate-pulsed dendritic cells in three patients with advanced ovarian cancer, measured in a 6 h
51Cr-release assay. Percentage lysis (standard deviation) at a 5:1 (empty columns), 10:1 (gray columns) and 20:1 (black columns) effector/
target cell ratio is shown. Anti-human leukocyte antigens class I blocking antibody (W6/32) and isotype control Mab (data not shown) were
used at 50mg/ml. Patients 1—3; 1, autologous tumor; 2, autologous tumorþW6/32 anti-class I MAb; 3, lymphoblastoid cell line control; 4, K562.
Killing of autologous tumor cells by TAL compared to PBL and TAL (P< 0.01). Killing inhibition by anti-HLA class I MAb in TIL compared to
PBL and TAL (P< 0.05).
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patients unresponsive to standard treatment modal-
ities. Consistent with this view, several human phase
I/II trials have been initiated using tumor antigen
pulsed DC, and promising clinical results have been
reported, in the absence of significant toxicity(33—38).
However, it is now apparent that the maturation stage
of DC is critical for their optimal use in immunization
strategies(22—24). Indeed, in vivo clinical studies have
shown that monocyte-derived mature DC rapidly
generate broad T-cell immunity in healthy subjects
vaccinated with less than 3106 antigen-pulsed auto-
logous DC(22,23). In contrast, the administration of
immature DC has been shown to result in inhibition
of pre-existing effector T-cell function(24), with recent
experiments also providing direct evidence that anti-
gen loaded immature DC may silence T-cells, either
by peripheral deletion, or expansion of regulatory
T-cells(39).
Patients with advanced ovarian cancer have often
been shown to progressively develop impaired
immune responses against autologous tumor cells,
preceding the development of a more generalized
state of immunosuppression(2—6,8—10). In several stud-
ies, diminished T-cell function has been correlated
with specific alterations in the T-cell signal transduc-
tion pathways, deletion of tumor-specific T lympho-
cytes by tumor cells, and induction of tolerance
against tumor antigens(1—10). Although the mechan-
isms responsible for these impaired immune
responses are yet not completely understood, it has
been recently shown that a population of tolerogenic
macrophages from tumor-bearing hosts have the cap-
ability to down-regulate cytotoxic T-cell responses
against tumor cells as well as to abrogate expression
of CD3-z chain by contact—dependent interac-
tions(40,41). Furthermore, a population of immature
DC endowed with low or absent expression of CD80
(B7.1), low expression of CD86 (B7.2), and the ability
to secrete high levels of immunosuppressive cyto-
kines (ie, IL-10 and TGF-b) have been recently identi-
fied in the peritoneal cavity of patients harboring
advanced ovarian cancer(14). It is therefore possible
that tumor-associated tolerogenic DC may play a
major role in the subversion of the immune system
commonly detected in the peritoneal cavity of ovarian
cancer patients(14). Adoptive transfusions of tumor-
specific in vitro activated T-cells, which avoid the
potential problems associated with inducing a CTL
response in vivo, might therefore be a more effective
approach for control of tumor growth in patients har-
boring advanced stage ovarian cancer.
Although the identity and distribution of antigenic
peptides and CTL epitopes presented by freshly
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Fig. 3. Representative dot plot analysis of intracellular interferon-g
and IL4 expression by CD8þ T-cells from peripheral blood
lymphocytes, tumor-associated lymphocytes and tumor-
infiltrating lymphocytes for an individual patient after in vitro
culture with tumor antigen-loaded dendritic cells. Lymphocytes
were activated by PMA and ionomycin as described in the method
section. Numbers in the quadrants represent the percentage of
CD8þ cytokine positive T lymphocytes.
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isolated epithelial ovarian tumors are still poorly
known, recent studies have unequivocally shown
that multiple tumor antigens do exist that can be
recognized by CTLs and used as target molecules to
induce autologous tumor cell killing in vitro(25,26,42).
Consistent with this view, we have recently shown the
in vitro induction from peripheral blood of tumor
specific CD8þ CTL in advanced ovarian cancer
patients using unfractionated tumor-derived antigens
either as whole tumor cell lysate or as acid-eluted
HLA class I-associated peptides isolated from tumor
cells(30,31). Tumor infiltrating lymphocytes represent a
population of antigen-experienced CD8þ T-cells which
have been previously demostrated to be endowed with
50—100 times stronger antitumor activity compare to
in vitro activated peripheral blood lymphocytes(43). TIL
could therefore represent a superior source of tumor
specific CTL to be used in the adoptive immunotherapy
for advanced ovarian cancer. However, the immuno-
competence of human TIL and the possibility to consist-
ently restore their tumor specific lytic activity in vitro
remain an unresolved issue.
In this study, as a basis for the development of
more effective immunotherapy protocols for the treat-
ment of this disease, we performed a careful pheno-
typic and functional analysis of lymphocytes derived
from PBL, TAL, and TIL before and after in vitro
stimulation with tumor antigen-pulsed autologous
mature DC.
We found TIL to be a consistently superior source
of tumor specific CTL compared to TAL and PBL.
Indeed, although not cytotoxic immediately after col-
lection (data not shown), suggesting that a state of
anergy exists in vivo, induction of higher cytotoxic
activity against autologous ovarian tumor cells was
consistently noted in TIL populations from all three
patients when compared to CD8þ T-cells derived
from PBL and TAL. The lack of significant cytotoxicity
against HLA-identical autologous LCL confirmed
that, although TIL-derived CTLs were highly cytolytic
against autologous tumor cells, they failed to kill
autologous control target cells expressing different
antigens. Furthermore, the fine specificity of the
TIL-derived populations of CTL was also confirmed
by the significantly higher block in cytotoxic activity
detected using anti-HLA class I Mab when compared
to TAL or PBL-derived CTL, and by their minor
cytotoxic activity against K562 natural killer sensitive
target cells.
It is worthy noting that while CD3þ T-cells were
the major lymphocyte population detected in each
tissue, lymphocytes used at the time of in vitro stimu-
lation with tumor antigen-pulsed DC were predomi-
nantly CD4þ T-cells in PBL and TAL, but not in TIL
(CD4:CD8 ratio: 3.1 versus 2.2 versus 1.0, respect-
ively). After in vitro restimulation with antigen
loaded fully mature DC, CD4 T-cells remained pre-
dominant in PBL and TAL cultures, while in TIL
cultures a predominant population of CD8þ T-cells
was consistently noted. CD56þ/CD16þ/CD3— NK
cells and CD8þ/CD56þ T-cells were predominant in
PBL compared to TAL and TIL at the beginning of
culture. However, after in vitro stimulation and expan-
sion of CD8þ T-cells, TIL contained a significantly
higher percentage of CD8þ/CD56þ T-cells compared
to TAL and PBL. These results were found to correlate
with a significantly higher cytotoxic activity in the
CD8þ CTL populations derived from TIL compared
to those derived from TAL and PBL. Taken together
these data support the view that, as previously
described by us(30,31) as well as others(44) in CD8þ T-
cells derived from peripheral blood, CD56 expression
on CD8þ T-cells derived from TIL is an activation
antigen associated with higher cytotoxic function,
rather than a lineage-specific marker.
In agreement with previous reports(4,7) we found a
lower relative expression of TcRz chain in freshly iso-
lated CD8þ T-cells derived from ovarian TIL and TAL
compared to PBL. However, no significant difference
in TcRz chain expression compared to PBL was
detected after in vitro stimulation of TAL and TIL
with fully mature ovarian tumor antigen loaded DC.
These data therefore demonstrate that tumor antigen
loaded-DC stimulation may provide culture condi-
tions able to induce restoration of TcRz chain expres-
sion in TAL and TIL to the level detected in activated
PBL populations.
Type 1 IFN-g producing T-cells are believed to pro-
mote the development of cell-mediated immunity
against viral infection as well as the control of
tumors(45,46). Consistent with this view, induction of
in vivo antitumor immune responses, as well as effect-
ive adoptive cellular immunotherapy, have been
reported to be more dependent on the induction of a
host immune response triggered by Type 1 cytokines
(ie, IL-2, IFN-g, GM-CSF) than the in vitro cytotoxic
activity of the responder or transferred lympho-
cytes(47,48). Recently, a significant dysfunction of
Type 1 T-cell responses concomitant with an abnor-
mally elevated production of Type 2 cytokines in
several human neoplasias has been reported(49) sug-
gesting that tumor progression may be associated
with a preferential and unprotective Type 2 T-cell
bias. In our previous work comparing the phenotype
of lymphocytes derived from PBL, TAL, and TIL in
several advanced ovarian cancer patients(50), IFN-g
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expression was predominant in the CD8þ T-cell
populations derived from TIL. Consistent with these
data, in all three patients studied in this report, IFN-g
expression was predominant in TIL compared to
the PBL and TAL-derived CD8þ T-cell populations.
IL-4þ T-cells were detected in low numbers and mainly
in PBL. After in vitro stimulation with tumor antigen-
pulsed DC, a greater proportion of IFN-gþ cells was
again detected in TIL as compared to TAL and PBL.
This pattern of cytokine expression further supports
the concept of a specific recruitment and accumula-
tion of a high concentration of antigen-experienced
tumor specific CD8þ T lymphocytes in the ovarian
tumor tissue(50,51). Furthermore, these data clearly
suggest that the lack of in vitro cytotoxic activity com-
monly detected in fresh TAL and TIL population is
not secondary to a Th2 cytokine switch.
In conclusion, we showed that lymphocytes
derived from TIL may constitute a superior source
of tumor specific HLA class I-restricted CTL com-
pared to TAL and PBL for adoptive immunotherapy
for advanced ovarian cancer. Although poor immune
responses by explanted T lymphocytes might be
expected, it is possible that this in vivo defective
immunologic response against ovarian tumors may
be normalized by in vitro T-cell stimulation with pro-
fessional antigen-presenting cells such as fully mature
DC. These results, combined with the fact that the
most critical component of successful adoptive immuno-
therapy of cancer is the identification and isolation
of large numbers of lymphocytes with potent and
specific antitumor activity, warrant further research
efforts for the development of improved protocols to
counteract mechanisms leading to impaired TAL and
TIL function, and thus exploit these populations for
use in adoptive cellular immunotherapy of advanced
ovarian cancer.
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